Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Central Nervous System Neoplasms 6Neuroblastoma 4Testicular Neoplasms 3Testicular Germ Cell Tumor 3Brain Neoplasms 3Seminoma 2Pheochromocytoma 2Ovarian Neoplasms 2Medulloblastoma 2Glioma 2Endodermal Sinus Tumor 2Thrombocytopenia 1Teratoma 1Microphthalmia, Isolated, with Coloboma 5 1Lymphoma 1Intraocular Lymphoma 1Gliosarcoma 1Glioblastoma 1Dysgerminoma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Embryonal 1

Interventions

Cyclophosphamide 35Temozolomide 33Filgrastim 26Etoposide 26Carboplatin 25Vincristine 22Cisplatin 22Radiotherapy 20Magnetic Resonance Spectroscopy 18Thiotepa 14Irinotecan 13Granulocyte Colony-Stimulating Factor 12Peripheral Blood Stem Cell Transplantation 11Lomustine 11Specimen Handling 9Radiation 9Melphalan 9etoposide phosphate 8Topotecan 8Methotrexate 8X-Rays 7Platinum 7Phantoms, Imaging 7sonidegib 6Biopsy 61,2-diaminocyclohexaneplatinum II citrate 6sargramostim 5palbociclib 5Nuclear Medicine Department, Hospital 5HhAntag691 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Medulloblastoma × pegfilgrastim × CNS × Clear all
NCT05535166 2026-02-12

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Recruiting
130 enrolled
CNS

Brain Neoplasms, Medulloblastoma

NCT04023669 2025-02-07

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

St. Jude Children's Research Hospital

Phase 1 Completed
21 enrolled
CNS

Microphthalmia, Isolated, with Coloboma 5, Brain Neoplasms, Medulloblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡